Path Forward For Viridian’s IGF-1R Antibody In Chronic TED Raises Questions
Pivotal Trial Amendment Controversial
The US firm’s potential rival to Horizon’s Tepezza, VRDN-001, showed positive signals in a small group of patients with chronic thyroid eye disease in a Phase I/II trial, but its decision to drop one planned dosing regimen from an upcoming pivotal trial has put off some analysts.
